Citation Impact
Citing Papers
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
2022 StandoutNobel
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
2016
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial
2018
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
2012
Clinical implications of the intrinsic molecular subtypes of breast cancer
2015
HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor
2015
Breast cancer
2019 Standout
The role of the insulin-like growth factor-1 system in breast cancer
2015
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
2021
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
Clinical implications of molecular heterogeneity in triple negative breast cancer
2015
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Smarter drugs emerging in pancreatic cancer therapy
2014
Triple-Negative Breast Cancer
2017
Breast cancer
2016 Standout
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
2018
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Macrophages in immunoregulation and therapeutics
2023 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
The biology and function of fibroblasts in cancer
2016 Standout
Triple-negative breast cancer: treatment challenges and solutions
2016
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
2016
Second international consensus guidelines for breast cancer in young women (BCY2)
2016
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)
2017
Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium
2020
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Extracellular matrix structure
2015 Standout
Pyroptosis: mechanisms and diseases
2021 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Deep learning in histopathology: the path to the clinic
2021 Standout
Recent Advances in the Treatment of Breast Cancer
2018
Management of breast cancer brain metastases: A practical review
2016
Collective cell migration in morphogenesis, regeneration and cancer
2009 Standout
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
2017 Standout
In vitro-engineered non-antibody protein therapeutics
2017
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
Dermal Lymphatic Emboli in Inflammatory and Noninflammatory Breast Cancer: A French-Tunisian Joint Study in 337 Patients
2005
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Targeting ferroptosis as a vulnerability in cancer
2022 Standout
De novo design of buttressed loops for sculpting protein functions
2024 StandoutNobel
Bone metastasis: the importance of the neighbourhood
2016
AKT/PKB Signaling: Navigating the Network
2017 Standout
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
2014 Standout
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
2016
The PI3K Pathway in Human Disease
2017 Standout
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
2020 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer
2017
Practical Approach to Triple-Negative Breast Cancer
2017
Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?
2018
Breast Cancer Statistics, 2022
2022 Standout
Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies
2017
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
2015
Breast Cancer Treatment
2019 Standout
Computational Evolution of Threonine-Rich β-Hairpin Peptides Mimicking Specificity and Affinity of Antibodies
2019 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Cancer treatment and survivorship statistics, 2019
2019 Standout
A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status
2018
Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis
2017
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Medical Management of Brain Metastases and Leptomeningeal Disease in Patients with Breast Carcinoma
2018
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline
2016
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Works of Timothy Pluard being referenced
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
2014
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
2016
CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer
2015
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
2015
Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2014
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
2017
Phase II trial of temsirolimus in patients with metastatic breast cancer
2012
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
2013
Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).
2016
Outcomes of High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in Stage IIIB Inflammatory Breast Cancer
1999
A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)
2010
Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc
2015